Obesity Clinical Trial
Official title:
Detraining Effect of Short-term HIIT on Cardiometabolic Risk in Young Adults With Obesity
The primary aim of this randomized clinical trial is to compare the effects of three different HIIT protocols and a control group on cardiometabolic health in young adults with obesity. Participants will be randomly assigned to one of the following three groups, with each having varying work-to-rest ratios: 1) HIIT-A, 2) HIIT-B, 3) HIIT-C, and 4) control group. HIIT-A, HIIT-B, and HIIT-C groups will participate in six sessions of a running based HIIT program over a 2-week training period. Pre-clinical markers of cardiovascular disease, blood lipids and fasting glucose will be measured at the following three time points: baseline, post-intervention, and 2 weeks after the training cessation (i.e., measure for detraining effect). All measurements will be performed three days before the training program and three days after the intervention to avoid the effect of the last training session. Afterwards, the detraining test will be measured 2 weeks post intervention.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | December 10, 2024 |
Est. primary completion date | February 10, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 25 Years |
Eligibility | Inclusion Criteria: - Young adults with obesity (Age 18 to 25 years old, BMI = 30 kg/m2). Exclusion Criteria: - Syndromic obesity; 1) Any clinical symptoms including cognitive delay, 2) abnormalities in body structure(s), 3) organ-specific abnormalities (kidney, liver failure, excessive eating, and/or other signs of hypothalamic dysfunction such as fatigue, weakness and/or lack of interest in activities. - Taking weight loss medication(s) - Currently enrolled (or within previous 6 months) in a weight loss program; - An underlying disease/medications (steroids, second generation psychotropic agents, hormonal contraception, statins, antihypertensive and antidiabetic medications) that could influence carbohydrate or lipid metabolism. - Presence of cardiac pacemaker. - Current or anticipated participation in another research that would interfere with any of the outcomes. - Current or anticipated pregnancy. |
Country | Name | City | State |
---|---|---|---|
United States | Women's Building | Syracuse | New York |
Lead Sponsor | Collaborator |
---|---|
Syracuse University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Height | Height (cm) | Baseline | |
Primary | Weight | Weight (kg); Change from Baseline weight at 2 week and 4 week | Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining) | |
Primary | Body mass index | Body mass index (kg/m2); Change from Baseline BMI at 2 week and 4 week | Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining) | |
Primary | Percentage body fat | Percentage body fat (kg); Change from Baseline percentage body fat at 2 week and 4 week | Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining) | |
Primary | Fat mass | Fat mass (kg); Change from Baseline fat mass at 2 week and 4 week | Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining) | |
Primary | Lean mass | Lean mass (kg); Change from Baseline lean mass at 2 week and 4 week | Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining) | |
Primary | Systolic blood pressure | Systolic blood pressure (SBP, mmHg); Change from Baseline SBP at 2 week and 4 week | Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining) | |
Primary | Diastolic blood pressure | Diastolic blood pressure (DBP, mmHg); Change from Baseline DBP at 2 week and 4 week | Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining) | |
Primary | Mean arterial pressure | Mean blood pressure (MAP, mmHg); Change from Baseline MAP at 2 week and 4 week | Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining) | |
Primary | Flow-mediated dilation | Flow-mediated dilation (FMD, mm); Change from Baseline FMD at 2 week and 4 week | Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining) | |
Primary | Carotid-femoral Pulse Wave Velocity (cPWV) | cPWV (m/s); Change from Baseline cPWV at 2 week and 4 week | Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining) | |
Primary | Total cholesterol | Total cholesterol (mg/dl); Change from Baseline TC at 2 week and 4 week | Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining) | |
Primary | LDL-C | LDL-C (mg/dl); Change from Baseline LDL-C at 2 week and 4 week | Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining) | |
Primary | HDL-C | HDL-C (mg/dl); Change from Baseline HDL-C at 2 week and 4 week | Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining) | |
Primary | Triglycerides | Triglycerides (TG, mg/dl); Change from Baseline TG at 2 week and 4 week | Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining) | |
Primary | Glucose | Glucose (mg/dl); Change from Baseline glucose at 2 week and 4 week | Baseline, post test (2 weeks of intervention), training cessation (2 weeks of detraining) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |